GlassScriptPhysician profile
Gregory J Shypula
NPI 1902869720
$2,499.88
in general payments reported to CMS, 2019-2025
28 companies · $777 in 2025
The $777 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $120 · 2020: $140 · 2021: $327 · 2022: $267 · 2023: $167 · 2024: $703 · 2025: $777.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,426 · Education: $221.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,425.87 |
| Education | $220.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $334.15 | 2022-2025 | Trodelvy |
| Incyte Corporation | $227.40 | 2019-2025 | Jakafi |
| E.R. Squibb & Sons, L.L.C. | $214.42 | 2021-2025 | Opdivo, Krazati, Opdualag |
| Astrazeneca Pharmaceuticals LP | $201.59 | 2024-2025 | Imfinzi, Tagrisso, Enhertu |
| Daiichi Sankyo INC. | $180.04 | 2021-2025 | Injectafer, Datroway |
| Janssen Biotech, INC. | $176.43 | 2019-2024 | Darzalex, Talvey, Tecvayli |
| Novartis Pharmaceuticals Corporation | $169.15 | 2019-2025 | |
| Pfizer INC. | $124.17 | 2019-2025 | |
| Abbvie INC. | $122.60 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $117.71 | 2019-2025 | |
| Amgen INC. | $113.59 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $112.86 | 2019-2025 | Keytruda, Lynparza |
| Celgene Corporation | $65.75 | 2022-2025 | Reblozyl |
| Agios Pharmaceuticals, INC. | $39.52 | 2024-2025 | Pyrukynd |
| Regeneron Healthcare Solutions, INC. | $36.31 | 2022-2025 | Libtayo |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $33.40 | 2022-2025 | |
| Blue Earth Diagnostics | $32.75 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.24 | 2024 | Ninlaro |
| Genzyme Corporation | $22.94 | 2025 | |
| Beone Medicines USA, INC. | $21.88 | 2025 | Tevimbra |
| Pharmacosmos Therapeutics INC. | $19.43 | 2024 | Monoferric |
| Glaxosmithkline, LLC. | $19.07 | 2025 | Ojjaara, Blenrep |
| Exelixis INC. | $18.12 | 2024 | Cabometyx |
| Array Biopharma INC | $17.55 | 2025 | Mektovi, Braftovi, Lorbrena |
| Emd Serono, INC. | $14.98 | 2021 | |
| Global Blood Therapeutics, INC. | $14.61 | 2021 | |
| Rigel Pharmaceuticals, INC. | $12.72 | 2021 | |
| Epizyme, INC. | $11.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Shypula listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.